| OBERMANNOVÁ, Radka, Dalibor VALÍK, Dirk HASENCLEVER, Lenka ZDRAŽILOVÁ DUBSKÁ, Ulrich HACKER, Regina DEMLOVÁ, Iveta SELINGEROVA and Florian LORDICK. High prevalence of severe hypovitaminosis D in patients with advanced gastric cancer treated with first-line chemotherapy with or without anti-EGFR-directed monoclonal antibody (EXPAND trial) showing no prognostic impact. European Journal of Cancer. Oxford: Elsevier Science Inc., 2019, vol. 116, JUL 2019, p. 107-113. ISSN 0959-8049. Available from: https://dx.doi.org/10.1016/j.ejca.2019.05.011. |
Other formats:
BibTeX
LaTeX
RIS
@article{1576199,
author = {Obermannová, Radka and Valík, Dalibor and Hasenclever, Dirk and Zdražilová Dubská, Lenka and Hacker, Ulrich and Demlová, Regina and Selingerova, Iveta and Lordick, Florian},
article_location = {Oxford},
article_number = {JUL 2019},
doi = {http://dx.doi.org/10.1016/j.ejca.2019.05.011},
keywords = {Vitamin D; 25-OHD plasma levels; Gastric cancer; Chemotherapy cetuximab; Prognosis},
language = {eng},
issn = {0959-8049},
journal = {European Journal of Cancer},
title = {High prevalence of severe hypovitaminosis D in patients with advanced gastric cancer treated with first-line chemotherapy with or without anti-EGFR-directed monoclonal antibody (EXPAND trial) showing no prognostic impact},
url = {http://dx.doi.org/10.1016/j.ejca.2019.05.011},
volume = {116},
year = {2019}
}
TY - JOUR
ID - 1576199
AU - Obermannová, Radka - Valík, Dalibor - Hasenclever, Dirk - Zdražilová Dubská, Lenka - Hacker, Ulrich - Demlová, Regina - Selingerova, Iveta - Lordick, Florian
PY - 2019
TI - High prevalence of severe hypovitaminosis D in patients with advanced gastric cancer treated with first-line chemotherapy with or without anti-EGFR-directed monoclonal antibody (EXPAND trial) showing no prognostic impact
JF - European Journal of Cancer
VL - 116
IS - JUL 2019
SP - 107-113
EP - 107-113
PB - Elsevier Science Inc.
SN - 09598049
KW - Vitamin D
KW - 25-OHD plasma levels
KW - Gastric cancer
KW - Chemotherapy cetuximab
KW - Prognosis
UR - http://dx.doi.org/10.1016/j.ejca.2019.05.011
L2 - http://dx.doi.org/10.1016/j.ejca.2019.05.011
N2 - Purpose: The goal of our analysis was to study pretherapeutic circulating 25-OHD plasma levels in patients with previously untreated advanced gastric cancer treated in the randomised controlled phase III Erbitux (cetuximab) in combination with Xeloda (capecitabine) and cisplatin in advanced esophago-gastric cancer (EXPAND) trial (NCT00678535) and to explore whether low 25-OHD plasma levels are associated with worse prognosis and may compromise the clinical efficacy of cetuximab. Methods: Six hundred thirty patients with available pretherapeutic 25-OHD plasma levels and treated with chemotherapy based on capecitabine and cisplatin, or chemotherapy and cetuximab, were included. The Cox proportional hazard regression model was used to analyse the association between low 25-OHD and survival in both treatment arms. Results: Majority of study patients were found to have severe vitamin D deficiency. No prognostic impact of 25-OHD plasma levels could be found in our patient cohort, and there was no indication of an interference of 25-OHD plasma levels and the efficacy of treatment with the anti-epidermal growth factor receptor monoclonal antibody cetuximab. Conclusions: Although majority of patients with advanced gastric cancer show hypovitaminosis D deficiency, there is no proof for a negative impact on survival or reduced treatment response. A prospective study is needed to investigate the potential benefit of vitamin D supplementation in this patient cohort during first-line chemotherapy. (C) 2019 Elsevier Ltd. All rights reserved.
ER -
OBERMANNOVÁ, Radka, Dalibor VALÍK, Dirk HASENCLEVER, Lenka ZDRAŽILOVÁ DUBSKÁ, Ulrich HACKER, Regina DEMLOVÁ, Iveta SELINGEROVA and Florian LORDICK. High prevalence of severe hypovitaminosis D in patients with advanced gastric cancer treated with first-line chemotherapy with or without anti-EGFR-directed monoclonal antibody (EXPAND trial) showing no prognostic impact. \textit{European Journal of Cancer}. Oxford: Elsevier Science Inc., 2019, vol.~116, JUL 2019, p.~107-113. ISSN~0959-8049. Available from: https://dx.doi.org/10.1016/j.ejca.2019.05.011.
|
